ARCHIVES

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 1 | January 31, 2014

Download PDF Visit The Full Archive

Related Articles

NCI To Stop All Support For WHT After March 31

February 5, 1988

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011

Also in this 8-page issue: NIH opens 240-bed Hatfield Clinical Research Center.

September 24, 2004

NIH reauthorization to be topic of July 19 hearing.

July 15, 2005

House Expected To Eliminate Earmarks, give NCI $2 Billion For FY94, A $40 Million Increase

June 18, 1993

Varmus Appoints Group On Intellectual Property

May 8, 1998